In a turbulent market environment marked by significant declines across major indices due to ongoing tariff concerns and geopolitical tensions, investors are increasingly seeking stability and potential growth opportunities. In such times, companies with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the business, aligning management's interests with shareholders' goals.

Top 10 Growth Companies With High Insider Ownership In The United States

Name Insider Ownership Earnings Growth Super Micro Computer (NasdaqGS:SMCI) 14.2% 29.8% Hims & Hers Health (NYSE:HIMS) 13.2% 21.8% Duolingo (NasdaqGS:DUOL) 14.4% 37.2% Credo Technology Group Holding (NasdaqGS:CRDO) 12.2% 65.1% Astera Labs (NasdaqGS:ALAB) 15.8% 61.4% Niu Technologies (NasdaqGM:NIU) 36% 82.8% Red Cat Holdings (NasdaqCM:RCAT) 19.4% 123% Clene (NasdaqCM:CLNN) 19.4% 63.1% Upstart Holdings (NasdaqGS:UPST) 12.6% 100.2% Credit Acceptance (NasdaqGS:CACC) 14.4% 33.8%

Click here to see the full list of 201 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Pagaya Technologies

Simply Wall St Growth Rating: ★★★★★☆

Overview: Pagaya Technologies Ltd. is a technology company that utilizes data science and AI-powered technology to serve financial services, other service providers, their customers, and asset investors in the U.S., Israel, and the Cayman Islands, with a market cap of approximately $711.57 million.

Operations: The company's revenue primarily comes from its Software & Programming segment, generating $1.03 billion.

Insider Ownership: 18.6%

Earnings Growth Forecast: 149.5% p.a.

Pagaya Technologies is positioned for substantial growth, with earnings forecasted to increase significantly at 149.51% annually. Despite a recent net loss of US$401.41 million for 2024, revenue rose to US$1.03 billion from US$812.05 million the previous year, indicating strong sales momentum. The company trades at a good value relative to peers and projects profitability by mid-2025, supported by expected network volumes between $10.25 billion and $11.75 billion for the full year 2025.

Delve into the full analysis future growth report here for a deeper understanding of Pagaya Technologies. The valuation report we've compiled suggests that Pagaya Technologies' current price could be quite moderate.NasdaqCM:PGY Ownership Breakdown as at Apr 2025

AvePoint

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AvePoint, Inc. offers a cloud-native data management software platform across North America, Europe, the Middle East, Africa, and the Asia Pacific with a market cap of approximately $2.93 billion.

Story Continues

Operations: The company generates revenue primarily through its Software & Programming segment, which accounts for $330.48 million.

Insider Ownership: 33.1%

Earnings Growth Forecast: 96% p.a.

AvePoint is poised for growth, with earnings expected to rise 95.98% annually and a forecasted transition to profitability within three years. Despite trading at 18.5% below its estimated fair value, the company reported a net loss of US$29.09 million for 2024 on revenues of US$330.48 million, up from US$271.83 million the previous year. Recent product launches and strategic acquisitions aim to enhance its SaaS offerings and global market presence, supporting future revenue expansion.

Take a closer look at AvePoint's potential here in our earnings growth report. The valuation report we've compiled suggests that AvePoint's current price could be inflated.NasdaqGS:AVPT Ownership Breakdown as at Apr 2025

Krystal Biotech

Simply Wall St Growth Rating: ★★★★★☆

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $4.87 billion.

Operations: Krystal Biotech generates revenue primarily from its business of developing and commercializing pharmaceuticals, amounting to $290.52 million.

Insider Ownership: 10.4%

Earnings Growth Forecast: 31.9% p.a.

Krystal Biotech demonstrates strong growth potential, with earnings expected to increase significantly at 31.9% annually and revenue projected to rise by 25.8% per year, outpacing the US market. Recent positive developments include a favorable recommendation from the European Medicines Agency for its product VYJUVEK®. The company reported substantial net income growth in 2024, reaching US$89.16 million from US$10.93 million in the previous year, while trading at a significant discount to its estimated fair value.

Click to explore a detailed breakdown of our findings in Krystal Biotech's earnings growth report. According our valuation report, there's an indication that Krystal Biotech's share price might be on the cheaper side.NasdaqGS:KRYS Ownership Breakdown as at Apr 2025

Where To Now?

Reveal the 201 hidden gems among our Fast Growing US Companies With High Insider Ownership screener with a single click here. Contemplating Other Strategies? Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include NasdaqCM:PGYNasdaqGS:AVPT and NasdaqGS:KRYS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments